Xenon Pharmaceuticals Inc.XENENASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +18.07% | +12.03% | +1.41% | +1.65% | +1.70% |
| Weighted Average Shares Diluted Growth | +18.07% | +12.03% | +1.41% | +1.65% | +1.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +16.52% | +68.08% | +938.30% | +28.60% | -13.43% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +24.56% | -17.27% | -19.12% | -23.72% | -27.28% |
| Book Value per Share Growth | +6.15% | -27.38% | -21.80% | -26.11% | -31.04% |
| Debt Growth | -11.06% | -17.32% | -16.79% | -13.14% | -14.91% |
| R&D Expense Growth | +32.86% | +44.79% | +38.31% | +50.87% | +35.25% |
| SG&A Expenses Growth | +30.47% | +42.68% | +34.15% | -0.81% | +15.42% |